Richard P Slaughter Associates Inc Has $221,000 Stake in Sanofi (NASDAQ:SNY)

Richard P Slaughter Associates Inc lessened its holdings in Sanofi (NASDAQ:SNY - Free Report) by 86.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,985 shares of the company's stock after selling 26,532 shares during the quarter. Richard P Slaughter Associates Inc's holdings in Sanofi were worth $221,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in SNY. Kentucky Trust Co bought a new stake in shares of Sanofi in the 4th quarter valued at about $436,000. Van ECK Associates Corp lifted its stake in shares of Sanofi by 18.1% in the fourth quarter. Van ECK Associates Corp now owns 662,762 shares of the company's stock worth $31,965,000 after acquiring an additional 101,726 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Sanofi by 128.0% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 115,330 shares of the company's stock valued at $5,558,000 after acquiring an additional 64,747 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Sanofi by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 257,655 shares of the company's stock valued at $12,427,000 after acquiring an additional 2,917 shares during the last quarter. Finally, abrdn plc increased its position in Sanofi by 25.6% during the 4th quarter. abrdn plc now owns 314,180 shares of the company's stock valued at $15,153,000 after purchasing an additional 64,095 shares during the period. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Up 1.5%

Shares of Sanofi stock traded up $0.74 during trading on Friday, reaching $50.50. 1,334,796 shares of the company traded hands, compared to its average volume of 2,700,300. The firm has a market capitalization of $123.84 billion, a PE ratio of 20.28, a P/E/G ratio of 1.01 and a beta of 0.50. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12. The company has a 50 day moving average price of $51.79 and a 200-day moving average price of $51.93. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.04. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The firm had revenue of $10.41 billion during the quarter, compared to the consensus estimate of $9.79 billion. During the same period in the previous year, the firm posted $1.78 earnings per share. The business's revenue was down 11.0% compared to the same quarter last year. As a group, equities research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be given a $2.0369 dividend. This represents a yield of 3.1%. This is a positive change from Sanofi's previous annual dividend of $1.48. The ex-dividend date is Friday, May 9th. Sanofi's payout ratio is presently 57.14%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on SNY. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. The Goldman Sachs Group began coverage on shares of Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 target price for the company. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research report on Tuesday. BNP Paribas assumed coverage on Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target for the company. Finally, Morgan Stanley set a $56.00 price objective on Sanofi in a research note on Monday. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, Sanofi presently has an average rating of "Buy" and a consensus price target of $61.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.